Novo Nordisk CEO Concedes Eli Lilly’s Market-Share Gains as Stock Slumps
Novo Nordisk's CEO conceded Eli Lilly is gaining market share even as oral Wegovy hits record prescriptions and the stock keeps falling.
Older stories
Novo Nordisk's CEO conceded Eli Lilly is gaining market share even as oral Wegovy hits record prescriptions and the stock keeps falling.
An unknown crypto whale lost $25.6 million after an attacker drained their wallet. The hacker swapped the stolen assets into Dai (DAI) and Ethereum (ETH), onchain analyst Specter reported. The same wallet lost $24.2 million to a phishing attack in…
ASX’s failed blockchain-based CHESS overhaul faces renewed governance scrutiny after the exchange admitted misleading the market.
Important TRX operations will once again be paused.
Qualifying new customers can receive full reimbursement, including fees, if they notify both the operator and law enforcement within 30 days.
The fund booked $344,849 in option gains, yet its cited NAV, Bitcoin and IBIT declines start on different dates.
The U.S. regulator of platforms such as Kalshi and Polymarket suggests the industry is getting into bad compliance habits that may allow for market abuse.
BofA's Aditya Bhave defends the bank's three-hike Fed forecast after July's CPI report, saying tightening remains incomplete.
Situational Awareness built a 16.61% Taiyo Yuden stake, then cut it to 4.41% during a hedge fund unwind.
U.S. spot Bitcoin ETFs absorbed about 13,300 BTC last week, more than four times the roughly 3,150 BTC newly created by the network.
The company had $7.6 million in cash as its biotech subsidiary began seeking resources for Phase 3.
Tokenized assets hit a record and trading activity jumped, but revenue slipped in the firm’s first earnings report since going public.